Transparency Market Research
Companion Diagnostic Tests in Oncology Market Size is Set to Achieve USD 17.0 Billion by 2034, with 9.5% CAGR: Transparency Market Research Inc.
09 sept. 2024 20h30 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- The global companion diagnostic tests in oncology market (الاختبارات التشخيصية المصاحبة...
VMR Logo.png
Immunoassay Market Surges to USD 39.66 Billion by 2031, Propelled by 4.67% CAGR - Verified Market Research®
05 août 2024 10h15 HE | Verified Market Research
Lewes, Delaware, Aug. 05, 2024 (GLOBE NEWSWIRE) -- The Global Immunoassay Market Size is projected to grow at a CAGR of 4.67% from 2024 to 2031, according to a new report published by Verified...
Olink Proteomics AB.png
Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery
03 juil. 2024 08h00 HE | Olink Proteomics AB
Inaugural network of Olink® Certified Service Providers includes eading contract research organizations (CROs) and service labs around the world.
ALLARITY Full Color RGB 2023JUN07.png
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
25 juin 2024 08h00 HE | Allarity Therapeutics, Inc.
Multiple patients have now exceeded 30 weeks on treatment Boston (June 25, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical...
PasitheaLogo.png
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
24 avr. 2024 07h59 HE | Pasithea
Pasithea Tx (Nasdaq: KTTA) Phase 1 trial on PAS-004 for RAS, NF1, and RAF mutated cancers completes initial dosing, with safety data expected in 2H 2024.
ALLARITY Full Color RGB 2023JUN07.png
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
27 mars 2024 08h30 HE | Allarity Therapeutics, Inc.
  The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
06 mars 2024 09h15 HE | Cyclacel
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
RTGN and TAG transparent 2023-12-04_15-50-47.png
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
22 févr. 2024 06h05 HE | RetinalGeniX Technologies, Inc.
RetinalGeniX Granted A New Patent for an Affordable and Effective Device and Method To Detect Ocular And Systemic Diseases
RTGN and TAG transparent 2023-12-04_15-50-47.png
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
26 déc. 2023 12h45 HE | RetinalGeniX Technologies, Inc.
RETINALGENIX AND MEDSAN CONTRACT TO ADVANCE STUDY INTENDED TO PERSONALIZE MEDICAL EVALUATIONS FOR PATIENTS RECEIVING TREATMENT FOR WET MACULAR DEGENERATION
RTGN and TAG transparent 2023-12-04_15-50-47.png
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
21 déc. 2023 05h50 HE | RetinalGeniX Technologies, Inc.
RETINALGENIX TECHNOLOGIES INC. APPOINTS ANATOLY DRITSCHILO, M.D. TO THE COMPANY’S MEDICAL ADVISORY BOARD